Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

Qiujun Shao, Simran Tiwana, Nicholas Despiegel, Franziska Dirnberger

Blood (2019) 134 (Supplement_1): 5814.

https://doi.org/10.1182/blood-2019-126309

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

Yanni Hao, PhD, Lamis K. Eldjerou, MD, Hongbo Yang, PhD, Cynthia Qi, MBA, Denise Globe, PhD

Blood (2017) 130 (Supplement 1): 609.

https://doi.org/10.1182/blood.V130.Suppl_1.609.609

Published: 2017

Journal Articles

The Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United Kingdom

Julia Snider, PhD, Michelle Brauer, BS, Yanni Hao, PhD, Pinar Karaca-Mandic, PhD, Mahlet Gizaw Tebeka, MS, Jie Zhang, PhD, Katharine Batt, MD MSc

Blood (2017) 130 (Supplement 1): 1330.

https://doi.org/10.1182/blood.V130.Suppl_1.1330.1330

Published: 2017

Journal Articles

Health Utility during the First Two Years of Treatment of Hematological Malignancies

Sonya Cressman, PhD, Mary Lynn Savoie, MD FRCPC, Stephen Couban, MD, Emily McPherson, Alexa Evans, Stuart Peacock

Blood (2016) 128 (22): 3608.

https://doi.org/10.1182/blood.V128.22.3608.3608

Published: 2016

Journal Articles

Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM)

Andrzej Jakubowiak, MD PhD, Istvan Matyas Majer, PhD, Ivan Houisse, MSc, Agnes Benedict, Marco Campioni, Sumeet Panjabi, Sikander Ailawadhi, MD

Blood (2016) 128 (22): 3582.

https://doi.org/10.1182/blood.V128.22.3582.3582

Published: 2016

Journal Articles

Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses

Cayla J. Saret, Aaron N. Winn, Gunjan Shah, Susan K. Parsons, Pei-Jung Lin, Joshua T. Cohen, Peter J. Neumann

Blood (2015) 125 (12): 1866–1869.

https://doi.org/10.1182/blood-2014-07-592832

Published: 2015

Includes: Supplemental data

Journal Articles

A Cost-Utility and Budget Impact Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Severe Thalassemic Patients In Thailand.

Suradej Hongeng, Samart Pakakasama, Nongnuch Sirachainan, MD, Ampaiwan Chuansumrit

Blood (2010) 116 (21): 1536.

https://doi.org/10.1182/blood.V116.21.1536.1536

Published: 2010

Journal Articles

A Disease Model to Predict the Long-Term Outcomes Associated with Treatments for Chronic Myelogenous Leukemia (CML).

Matthew Taylor, PhD, Lily Lewis, BSc, Thomas Patton, MSc, Ishan Hirji, BSP(Pharm), MPH, Catherine Davis, PharmD

Blood (2010) 116 (21): 4480.

https://doi.org/10.1182/blood.V116.21.4480.4480

Published: 2010

Journal Articles

A Cost-Effectiveness Analysis of Coagulation Testing Prior to Tonsillectomy and Adenoidectomy in Children.

James D. Cooper, MD, Kenneth J Smith, MD, MS, Arthur Kim Ritchey, MD

Blood (2008) 112 (11): 1294.

https://doi.org/10.1182/blood.V112.11.1294.1294

Published: 2008

Journal Articles

Choosing First-Line Therapy for Follicular Lymphoma (FL): A Decision Analysis

Rebecca L. Olin, MD, Peter A. Kanetsky, PhD, MPH, Thomas Ten Have, PhD, MPH, Sunita Dwivedy Nasta, MD, Stephen J. Schuster, MD, Charalambos Andreadis, MD, MSCE

Blood (2008) 112 (11): 670.

https://doi.org/10.1182/blood.V112.11.670.670

Published: 2008

Journal Articles

Assessment of the Economic Value of the Intercept Blood System for Platelets in Belgium.

Karen Moeremans, MD, Hans Warie, MD, Lieven Annemans, PhD, Toon Digneffe, MSc, Jacques Toté, MSc, Laurence Corash, MD

Blood (2004) 104 (11): 3156.

https://doi.org/10.1182/blood.V104.11.3156.3156

Published: 2004

Journal Articles

Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis

Paul J. Nietert, Miguel R. Abboud, Marc D. Silverstein, Sherron M. Jackson

Blood (2000) 95 (10): 3057–3064.

https://doi.org/10.1182/blood.V95.10.3057

Published: 2000

Journal Articles

The Costs and Cost-Effectiveness of Unrelated Donor Bone Marrow Transplantation for Chronic Phase Chronic Myelogenous Leukemia

Stephanie J. Lee, Claudio Anasetti, Karen M. Kuntz, Jonathan Patten, Joseph H. Antin, Jane C. Weeks

Blood (1998) 92 (11): 4047–4052.

https://doi.org/10.1182/blood.V92.11.4047

Published: 1998

NARROW

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

Cost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

The Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United Kingdom

Health Utility during the First Two Years of Treatment of Hematological Malignancies

Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM)

Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses

A Cost-Utility and Budget Impact Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Severe Thalassemic Patients In Thailand.

A Disease Model to Predict the Long-Term Outcomes Associated with Treatments for Chronic Myelogenous Leukemia (CML).

A Cost-Effectiveness Analysis of Coagulation Testing Prior to Tonsillectomy and Adenoidectomy in Children.

Choosing First-Line Therapy for Follicular Lymphoma (FL): A Decision Analysis

Assessment of the Economic Value of the Intercept Blood System for Platelets in Belgium.

Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis

The Costs and Cost-Effectiveness of Unrelated Donor Bone Marrow Transplantation for Chronic Phase Chronic Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only